30 closest matches · ranked by relevance
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · Acute Myeloid Leukemia (AML)
Primary: MTD (Stage 1) — 12; 12; 16 µg/kg/day
Leukemia, Acute Lymphoblastic
Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…
Myeloid Leukemia, Chronic, Accelerated Phase · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Primary: Percent of Participants With Major Hematologic Response (MaHR) With 6 Months of Follow-up From Date of Last Enrollment - Randomized Population — 48.0; 47.9 percentage of…
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Chronic Myeloid Leukemia · Blast Crisis
Primary: Major and Overall Hematologic Response (MaHR and OHR) — 2; 34; 36; 4 Participants
Leukemia
Primary: Disease-Free Survival at 2-Year Post-Transplant — 0.65 Proportion of pts alive in remission
Accelerated Phase Chronic Myelogenous Leukemia · Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Blastic Phase Chronic Myelogenous Leukemia
Primary: Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical…
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Lymphoblastic Leukemia, Acute
Primary: Rate of Hematological Complete Remission (HCR) Obtained During the BMS Induction Treatment Within Day +85 From the Start of BMS (i.e., Whenever Achieved From the Start…
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
B-cell Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle — 77.0 percentage of participants
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment — 80.0 percentage of participants — p=0.0000
Acute Lymphoblastic Leukemia
Primary: Number of Participants With Toxicities — 0 Participants
Hematologic Malignancies
Primary: Incidence of Greater Than or Equal to 50% Donor Chimerism — 100 percentage of participants
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
High-risk Diffuse Large B-Cell Lymphoma
Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants
Philadelphia Chromosome Positive CML
Primary: Overall Survival — 89.2 percentage of participants
Myeloid Leukemia, Chronic, Chronic-Phase
Primary: Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up — 51.8; 49.0 percentage of Participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912) — 22; 39; 43 percentage of participants
Multiple Myeloma, Relapsed · Multiple Myeloma, Refractory to Standard Treatment
Primary: Maximum Tolerated Dose (MTD) of Gy — NA Participants
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome
Primary: Assessment of Donor Stem Cell Engraftment: ANC Count — 33; 0 Participants
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
Adult Acute Lymphoblastic Leukemia in Remission · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Blastic Phase
Primary: Relapse Free Survival — 3 Participants
Leukemia
Primary: Percentage of Participants Reaching Disease Free Survival — 45.8 percentage of participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
B-Cell Non Hodgkin Lymphoma
Primary: Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR) — 22.0 Percentage of participants
Leukemia
Primary: Number of Participants Who Died, Experienced Other Serious Adverse Events (SAEs), Adverse Events (AEs) and AEs Leading to Study Drug Discontinuation. — 3; 2; 1; 1…
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants